CADTH Canadian Drug Expert Committee recommendation: Tofacinitib (Xeljanz) indication: for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate response, loss of response or intolerance to either conventional UC therapy or a tumor necrosis factor-alpha inhibitor (TNFi)
The CADTH Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be reimbursed for the treatment of adult patients with moderately to severely active UC with an inadequate response, loss of response, or intolerance to either conventional UCtherapy or a TNFi
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2019, March 2019
|
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that tofacitinib be reimbursed for the treatment of adult patients with moderately to severely active UC with an inadequate response, loss of response, or intolerance to either conventional UCtherapy or a TNFi |
---|---|
Physical Description: | 1 PDF file (8 pages) |